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Materials and Methods: Type of study : Descriptive study 
24 Eligible patients with age less than 61 years were included in this 
study from October 2011. Informed consent was obtained. Dental 
prophylaxis was carried out in all before the treatment. The patients 
were treated after evaluation and according to the stage of the 
disease. 13/24patients (54.16%) were locally advanced and 11/24 
patients (45.83%) were early stage. All of them received treatment as 
per protocol. Early stages T1/T2 and N0 were treated with EBRT 
(bilateral opposing fields or anterolateral wedge field to face and 
neck) dose of 44 Gy followed by 6 Gy with off cord (total dose 
50Gy/25#) was given to the primary as well as the regional lymph 
nodes of upper neck. This was followed by HDR interstitial 
brachytherapy boost of 2.5Gy per fraction or 3.5Gy per fraction for 6 
fractions twice daily with 6 to 8hrs interval between two fractions. 
Low anterior neck field (for lymph nodes) received 50 Gy per 25 
fractions. Locally advanced T1-T3 with N1, N2a, N2b or T3N0 diseases 
were treated similarly as mentioned above along with concurrent 
chemotherapy Cisplatin (70 mg/m2 every 3 weeks) and 16 Gy Electron 
boost/photon boost (if nodes are involved). Under general 
anaesthesia, trocars and hollow needles were inserted as guide tubes 
in and around the tumour 1cm apart in a single or multiple planes 
through which plastic tubes were threaded. These tubes were then 
secured by buttons. On 2nd post op day patients were simulated with 
CT scan. The CT images were transferred to the treatment planning 
system. The target was delineated in the planning system and 3D 
treatment plan was made to deliver the dose to the target. The effect 
of treatment was assessed by clinical examination as well as by 
imaging techniques if required on follow up. 
Results: High-dose-rate brachytherapy was tolerated by all patients. 
Only 2/24 (0.08%) patients developed bleeding complication. Local 
control was seen in 83.33% of patients among which 9/11 patients 
(81.8%) were in early stage and 11/13 (84.61%) patients were in 
locally advanced stage. (This is an ongoing study.) 
Conclusions: High-dose-rate brachytherapy as a boost for patients 
with primary squamous cell carcinomas of the oral cavity will help 
improve local control. It limits the volume of tissue exposed to high 
doses of radiation therapy. It has showed effective local control in 
early and locally advanced stages. 
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Purpose/Objective: Glomus tumors are rare tumors that are highly 
vascular and typically radiosensitive. Therapeutic options include 
surgery, radiation therapy, embolisation or any combination, but the 
appropriate treatment still remains challenge. The aim of this article 
is to report the results local control of 7 patients with glomus tumors 
treated with surgery and external beam radiotherapy at the Institute 
of Oncology and Radiology of Serbia.  
Materials and Methods: Follow-up was calculated from the date of 
initiation of RT for all patients. Patients had minimum follow-up time 
as 3 years and maximum follow-up as 15 years (mean, 7,14 years, 
median 6,2).The likelihood of local control was analyzed using the 
Kaplan-Meier product limit method. We also analyzed average 
duration of response between two groups of patients with different 
dose of radiation as well as presence of acute and late complications 
of RT.  
Results: Local control was obtained in 85,7% treated patients (6 of 7 
patients). Moreover, local control was achieved in 75% of treated 
patients with recurrent glomus tumors (3 of 4 patients),while in 
patients with residual disease local control was obtained in 100% of 
patients (3 of 3 patients). In our study, patients who received 
radiation therapy with dose less than 50Gy (2patients) had shorter 
average duration of response compared to patients who received 
higher than 50Gy (5 patients). There were no severe treatment 
complications. 
Conclusions: Surgery and radiation therapy are appropriate treatment 
approach for advanced glomus tumors with acceptable complications. 
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Purpose/Objective: The purpose of this retrospective cohort study 
was to identify clinical factors and/or DVH parameters associated with 
acute oral and pharyngeal toxicities (feeding tube, FT rate used as 
surrogate) in head and neck cancer patients treated with definitive 
chemoradiotherapy (CRT). 
Materials and Methods: From 2005-10, 174 patients with unknown 
primary (UKP)(n=18), oropharyngeal (n=122) and nasopharyngeal 
(n=33) squamous cell carcinoma (SCC) were prospectively treated with 
definitive radiotherapy (RT), with or without chemotherapy (CT). 
Median age was 54 years (range, 17-80). One, 13, 31, 107 and 4 
patients presented with stage I, II, III, IVa and IVb disease, 
respectively. Neoadjuvant chemotherapy (CT) was administered in 123 
patients (70%). Cisplatin (Cis) (n=100), carboplatin (Cb) (n=29) or Cis 
followed by Cb (n=20) based CT were given concomitantly with RT. 
Patients were treated with IMRT, delivering 65 Gy in 30 daily fractions 
to PTV1 (macroscopic disease) and 54 Gy in 30 daily fractions to PTV2 
(lymph nodes at risk, or nasopharyngeal mucosa for the UKP cancer 
patients). Reactive as opposed to prophylactic FT insertion policy was 
used. Acute toxicity (NCICTCv.2.0) was recorded prospectively at 
weeks 1–6 during and 1–4 post treatment. Organs at risk potentially 
involved in acute mucosal toxicity and swallowing including the 
superior, middle and inferior pharyngeal constrictor muscles and the 
oral (OM) and pharyngeal mucosae (PM) were delineated on the 
planning CT-scan. Dosimetric and clinical variables including N stage, 
age, gender, type of chemotherapy, smoking status, alcohol 
consumption and RT timing (8-11am vs 11-3pm vs 3-6 pm) were 
entered in a logistic regression analysis. 
Results: Severe acute dysphagia (FT) (Grade 3-4) and severe oral 
mucositis were observed in 85 (49%) and 88 (50%) patients, 
respectively. On univariate analysis, the mean dose to the OM and Cis 
based concomitant CT were significant factors for developing G≥3 oral 
mucositis (p=0.039 and p=0.013, respectively). As expected, patients 
who presented with an UKP SCC developed less G≥3 mucositis 
(p=0,012). These variables remain statistically significant in the 
multivariate analysis. FT rate was also significantly associated with 
the administration of Cis based concomitant CT (50 vs 46%, p=0.045). 
The maximum dose to the OM was also a significant prognostic factor 
for FT. These two variables remain significant in the multivariate 
logistic regression model. A statistical trend was observed, in 
addition, for patients receiving or not cisplatin-5FU induction CT, the 
later presenting less Grade ≥3 acute dysphagia: 55% vs. 41%, 
respectively (p=0.08). None of the other clinical variables mentioned 
above (dose to the constrictors and pharyngealmucosa in particular) 
correlated significantly with FT rates. 
Conclusions: The incidence of acute oral and pharyngeal toxicities 
remain high in head and neck patients treated with CRT. Type of 
chemotherapy and dose distribution to the oral mucosa alone seem to 
be of particular significance. 
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Purpose/Objective: Significant anatomical and volumetric changes 
occur in H&N cancer patients during fractionated radiotherapy (RT). 
The aim of this study was to assess the dosimetric changes and 
investigate its correlation to clinical parameters during a 6 week 
curative course of RT for H&N squamous cancers (HNSCC). 
Materials and Methods: Seventeen patients of HNSCC treated with 
inversed planned image guided IMRT using Tomotherapy Hi-Art was 
selected. The Planning Target volume (PTV) and organs at risk (OARs) 
including bilateral parotids and constrictor muscles were contoured. 
Daily megavoltage CT (MVCT) scans were acquired during treatment as 
per institutional policy; of which ones during fraction 1,15 and 30 was 
used to calculate changes in the dose to the PTV, constrictors and 
parotids. Patient’s weight, mid upper arm circumference (MUAC), mid 
arm muscle circumference (MAMC) and triceps thickness (TS) were 
recorded prior to, midway and at completion of RT (30th fraction). 
Correlation coefficients between the dosimetric and clinical changes 
was calculated to investigate whether it was possible to predict 
dosimetric changes using early clinical variables. 
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Results: No statistically significant changes to the PTV dose was noted 
during treatment (p= 0.8). Dose to the parotid glands (left and right 
respectively) changed significantly between the 1st and 30th fractions 
(p=0.02 and 0.01 respectively). Percentage weight loss between RT 
was significant (P=0.01) between the 1st and 30th fraction, as was the 
difference in the TS (p=0.02). There was no statistically significant 
difference in MUAC and MAMC. A negative correlation was found 
between the changes in weight (3.5%) between pre to mid treatment, 
with that of increased parotid gland dose. This leads us to hypothesize 
that a weight loss above 3.5% in the first half of treatment could 
potentially alert clinicians of likely dose increase in the parotid 
glands, necessitating adaptive planning strategies. 
Conclusions: There is a significant increase in dose to the parotid 
glands during treatment although the dose to the PTV remains 
relatively stable. Weight loss and Triceps thickness changes were the 
two most significant clinical parameters that changed during 
radiation. A negative correlation existed between early changes of 
these clinical factors and overall parotid dose changes during 
radiotherapy. A prospective study with more patients could now be 
designed to ascertain if a threshold percentage difference in Weight 
loss and TS changes could predict a significant parotid dose change.  
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Purpose/Objective: Numerous clinical trials have demonstrated that 
the loco-regional control and disease specific survival in patients with 
HNSCC can be significantly improved by reducing the total treatment 
time by the so called 'accelerated fractionation'. Such principle has 
most recently been demonstrated and confirmed in a large 
international randomized trial conducted by the IAEA as well as by a 
recent meta-analysis. The problems of overcoming hypoxia in head 
and neck cancers have been addressed in numerous clinical trials 
using different kinds of hypoxic modification and both the experience 
from major individual controlled clinical trials as well as a meta-
analysis has shown that such modification of hypoxia results in 
significantly better local control, disease-specific and overall survival. 
Repopulation and hypoxia are independent factors, and it is thus to be 
expected that the optimal treatment option is a reduced treatment 
time using concomitant hypoxic modification. Such treatment 
principle is also applied by some institutions and collaborative groups 
(such as DAHANCA), but the true value of adding a hypoxic modifier to 
a treatment schedule with accelerated fractionation has not been 
evaluated in a controlled clinical trial. 
Materials and Methods: A stratified, randomized phase III study of 
patients with HNSCC randomizes to accelerated radiotherapy ± 
Nimorazole. Radiotherapy will be given for both arms in 6 
fractions/week for a total dose 66-70Gy in 33-35 fractions & 
Nimorazole is to be administered in doses of approximately 1.2 g/m2 
body surface, 90 minutes prior to the first daily fraction. Quality 
assurance procedures are applied to ensure consistency and validity of 
the data. Biological materials are collected from the participating 
centers for analysis for hypoxia gene expression, as well as HPV/p16 
expression. 
Results: Patient recruitment started by the first of March 2012. 6 
centers out of 9 centers started patient’s recruitment. 47 patients are 
recruited to the trial by the beginning of December 2012. Collection 
of patient data is done through online electronic forms. Each center is 
asked to submit the radiotherapy treatment documentations of the 
first 5 recruited patients. Centers that use IMRT/3DCRT planning 
techniques are asked to upload the electronic plans of the first 5 
recruited patients on a specific FTP site. All plans are reviewed 
centrally in the trial central department by the quality assurance 
coordinator. Electronic plans could be viewed using virtual planning 
software. 
Conclusions: The trial is feasible to conduct in the participating 
centers. And treatment will be given with good quality standards. 
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Purpose/Objective: Human Papilloma Virus (HPV) status has evolved 
as one of the most important prognostic factors in head and neck 
cancer. We analyzed the relative impact of HPV-status and advanced 
radiotherapy (RT) techniques on outcome.  
Materials and Methods: Between Oct 2005 and Dec 2008 74 pts 
received definitive RT for oropharingeal cancer. In 62 pts we could 
retrospectively analyze HPV status by p16 immunohistochemistry and 
molecular analysis for HPV. P16 immunohistochemistry staining was 
performed using the CINtec® Histology V-Kit for qualitative detection 
of p16 antigen on tissue section. Both nuclear and/or cytoplasmic p16-
staining were considered to be positive. For HPV molecular biology, 
DNA extraction was performed using a Qiagen Kit. Molecular analysis 
was performed by nested PCR (AB-Analitica Kit). Mean age was 63 
years (35-84) and 84,7% of pts were male. Thirty-five pts (56.5%) 
presented with stage IV disease (all M0); 17 pts (27.4%) had base of 
tongue cancer and 34 pts (54.8%) had tonsillar cancer. In 33 pts 
(53,2%) RT was associated with concomitant chemotherapy with cis-
platinum. Seventeen pts (27.4%) underwent 3D simplified RT (3D-S, 
three field treatment with a single isocenter), followed by a 
photon/electron beam junction treatment and a 3D-conformal boost 
with a dose of 50 Gy to elective lymph node areas (CTV1) and 70 Gy to 
primary tumor and positive lymph nodes (CTV2). Twenty-two pts 
(35.5%) received 3D advanced RT (3D-A, 5 or 7 field conformal 
therapy) with doses of 50 Gy to CTV1 and 70 Gy to CTV2. Twenty-
three pts (37.1%) underwent intensity modulated RT (IMRT) with 
simultaneous integrated boost (SIB) with 2 dose levels (54-66 Gy in 30 
fractions) or 3 dose levels (54-60-69 Gy in 30 fractions). 
Results: Twenty-six pts. were P16+ (43,3%), 27 pts were PCR+ (45%) 
for HPV 16 and only one for HPV 18. Only 59 pts could be evaluated 
(two patients were lost to follow up at the time of analysis). Mean 
over all follow up is 39 months (3-80). OS, DFS and loco-regional 
control (LRC) at 3 and 5 years were 57,1,%, 51,9% and 79,6% and 
50,8%, 45,4%, 77,2% respectively. Univariate analysis based on the 
Kaplan-Meyer method (SPSS software) resulted in the identification of 
the following prognostic factors:  
Significant prognostic factor 
for OS 
p Significant prognostic factor 
for DFS 
p 
Smoking (cut-off > 10 pack 
years) 
,006 Smoking (cut-off > 10 pack 
years) 
,02 
Performance status (IK cut-
off 80) 
,000 Performance status (IK cut-off 
80) 
,000 
p16-positivity  ,000 p16-positivity  ,001 
PCR-positivity for HPV  ,007 PCR-positivity for HPV  ,03 
Treatment technique ,000 Treatment technique ,02 
 
LRC of P16+ pts was not influenced by treatment technique while in 
the HPV- cohort the 3 years DFS of pts treated with 3D-S, 3D-A and 
IMRT were 45,5%, 75% and 78% respectively, though these differences 
did not reach statistical significance for the relatively small number of 
patients. 
Conclusions: New techniques seem to be more relevant in outcome of 
p16 negative pts than in p16 positive pts probably because they allow 
a better high dose coverage of the target which may be more relevant 
in these prognostically less favourable patients. Further studies must 
be performed to confirm this hypothesis.  
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